For example, the phase 1/2 ZUMA-6 trial was designed to assess the value of treating refractory or relapsed high-grade DLBCL with a combination of CAR-T cell therapy and monoclonal antibody targeting PDL-1 [72]. Here, CD274 is linked to diffuse large B-cell lymphoma.